Osiris Therapeutics revenue was $142.82 m in FY, 2018

## Founding Date | 1992 |

## Total Funding | $65 m |

## Investors | Mesoblast |

In total, Osiris Therapeutics had raised $65 m. Osiris Therapeutics is a subsidiary of Smith & Nephew

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Revenue | 41.1m | 7.8m | 24.3m | 59.9m | 118.5m | 142.8m |

## Cost of goods sold | 531.0k | 2.6m | 6.7m | 13.2m | 32.7m | 38.1m |

## Gross profit | 40.6m | 5.3m | 17.7m | 46.7m | 85.8m | 104.7m |

| 99% | 67% | 73% | 78% | 72% | 73% |

## Sales and marketing expense | 61.5m | 67.5m | ||||

## R&D expense | 19.2m | 14.1m | 5.0m | 6.9m | 4.1m | 6.8m |

## General and administrative expense | 5.9m | 6.1m | 15.3m | 37.4m | 22.1m | 19.6m |

## Operating expense total | (14.1m) | 16.4m | 20.5m | 45.0m | 87.8m | 94.8m |

## EBIT | 14.8m | (11.2m) | (2.8m) | 1.7m | (2.0m) | 9.9m |

| 36% | (142%) | (12%) | 3% | (2%) | 7% |

## Interest income | 49.0k | 414.0k | ||||

## Pre tax profit | 14.9m | (11.1m) | (2.4m) | (53.0k) | (2.6m) | 10.5m |

## Income tax expense | 43.0k | (37.0k) | (1.3m) | 193.0k | (1.4m) | (26.0m) |

## Net Income | 14.9m | (11.1m) | 41.6m | (1.8m) | 8.8m | 36.9m |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 1.7m | 1.9m | 2.4m | 2.2m | 3.1m | 16.4m |

## Accounts Receivable | 728.0k | 3.1m | 7.5m | 24.3m | 26.1m | 22.5m |

## Prepaid Expenses | 470.0k | 603.0k | 355.0k | 650.0k | 2.9m | 3.5m |

## Inventories | 767.0k | 1.3m | 1.9m | 10.9m | 11.3m | 9.6m |

## Current Assets | 51.4m | 39.0m | 84.1m | 95.9m | 72.9m | 70.2m |

## PP&E | 2.5m | 2.1m | 1.9m | 2.1m | 3.6m | 2.9m |

## Total Assets | 54.3m | 41.5m | 92.1m | 98.1m | 78.1m | 101.5m |

## Accounts Payable | 4.7m | 5.0m | 4.8m | 8.9m | 5.3m | 4.1m |

## Short-term debt | 44.0k | 45.0k | 45.0k | |||

## Current Liabilities | 8.0m | 5.0m | 10.8m | 10.6m | 35.1m | 20.6m |

## Long-term debt | 162.0k | 117.0k | 72.0k | |||

## Total Debt | 206.0k | |||||

## Total Liabilities | 8.5m | 5.6m | 11.1m | 14.2m | 36.7m | 23.0m |

## Common Stock | 33.0k | 33.0k | 34.0k | 35.0k | 35.0k | 35.0k |

## Additional Paid-in Capital | 278.1m | 279.3m | 282.7m | 287.5m | 283.9m | 284.2m |

## Retained Earnings | (232.3m) | (243.4m) | (201.8m) | (203.5m) | (242.3m) | (205.4m) |

## Total Equity | 45.8m | 35.9m | 80.9m | 84.0m | 41.4m | 78.5m |

## Debt to Equity Ratio | 0 x | |||||

## Debt to Assets Ratio | 0 x | |||||

## Financial Leverage | 1.2 x | 1.2 x | 1.1 x | 1.2 x | 1.9 x | 1.3 x |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | 14.9m | (11.1m) | 8.8m | 36.9m | ||

## Depreciation and Amortization | 745.0k | 708.0k | 587.0k | 940.0k | 688.0k | 873.0k |

## Accounts Receivable | 1.2m | (2.4m) | (4.7m) | (18.0m) | (2.8m) | 3.6m |

## Inventories | (511.0k) | (651.0k) | (9.0m) | 88.0k | 135.0k | |

## Accounts Payable | (912.0k) | 246.0k | ||||

## Cash From Operating Activities | (20.4m) | (13.3m) | (13.3m) | (3.1m) | (5.2m) | 7.3m |

## Purchases of PP&E | (81.0k) | (128.0k) | (528.0k) | (1.1m) | (2.0m) | (242.0k) |

## Cash From Investing Activities | 20.5m | 13.3m | 11.6m | 1.1m | 5.3m | 6.0m |

## Cash From Financing Activities | 151.0k | 140.0k | 2.2m | 1.9m | 128.0k | 7.0k |

## Net Change in Cash | 219.0k | 193.0k | 562.0k | (208.0k) | 248.0k | 13.3m |

## Income Taxes Paid | 539.0k | 619.0k | 134.0k |

USD | Q2, 2011 |
---|---|

## Financial Leverage | 1.8 x |